glp-1 plus gip Understand GLP-1/GIP Dual Agonist Tirzepatide and Its Effect on Current Weight Loss Therapy Possible mechanisms of the interaction

As of 2024, Colorado had an obesity rate of 25%

The glucagon component appears to be the differentiator

There is no one-size-fits-all answer for how to microdose semaglutide or tirzepatide, and each protocol must be carefully individualized based on patient assessment and metabolic factors

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

It is the job of the L cells to secrete GLP-1s and PYY to stimulate insulin secretion from the pancreatic beta cells, inhibit glucagon release, and slow gastric emptying after a meal